Genprex, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Genprex, Inc. (GNPX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-30
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-30 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-13 | 0.00% 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-09 | 0.00% 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-04-01 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-13 | 0.00% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-09 | 0.00% 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 0.00% 10-K · filed 2022-03-30 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-26 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-11 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | 0.00% 10-K · filed 2020-03-30 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |